<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>202W92 (R-(-)-2,4-diamino-6-(fluromethyl)-5-(2,3,5-trichlorophenyl)<z:chebi fb="0" ids="16898">pyrimidine</z:chebi>) is a novel compound in the same chemical series as the <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drug lamotrigine and the neuroprotective sipatrigine </plain></SENT>
<SENT sid="1" pm="."><plain>Here 202W92 was quantitatively assessed as a neuroprotective agent in focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>, and as an inhibitor of <z:chebi fb="199" ids="26708">sodium</z:chebi> and calcium channels and of synaptic transmission </plain></SENT>
<SENT sid="2" pm="."><plain>In the rat permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model of <z:hpo ids='HP_0011009'>acute</z:hpo> focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, 202W92 reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 75% in cortex and by 80% in basal ganglia, with ED(50) approximately 2 mg/kg (single i.v. dose, 10 min post-occlusion) </plain></SENT>
<SENT sid="3" pm="."><plain>In whole-cell current recordings from single cells, 202W92 completely and reversibly inhibited voltage gated <z:chebi fb="199" ids="26708">sodium</z:chebi> channels (IC(50) 3 x 10(-6) M) in rat freshly-isolated cortical neurons and in the GH(3) pituitary cell line </plain></SENT>
<SENT sid="4" pm="."><plain>202W92 also inhibited a <z:chebi fb="1" ids="7565">nifedipine</z:chebi>-sensitive fraction (approximately 35%) of native high-voltage-activated (HVA) calcium current in rat cortical neurons (IC(50) 15 x 10(-6) M) and weakly inhibited low-voltage-activated (LVA) calcium currents of the recombinant alpha1I-mediated T-type (IC(50)&gt;100 x 10(-6) M) </plain></SENT>
<SENT sid="5" pm="."><plain>The drug inhibited the amplitude and frequency of <z:chebi fb="0" ids="34385">4-aminopyridine</z:chebi>-evoked glutamatergic excitatory post-synaptic currents (EPSCs) </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, 202W92 is an effective neuroprotective agent when administered post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and a potent <z:chebi fb="199" ids="26708">sodium</z:chebi> channel inhibitor in vitro </plain></SENT>
</text></document>